ABSTRACT: In the development of targeted cancer immunotherapies, the choice of antigen is ohviously critical to the design of any therapeutic strategy, bur particularly so for tumor vaccines, which must distinguish malignant eells from normal cells.! Investigations a decade ago focused on mutated rumor antigens, or viral tumor antigens, with the belief that these foreign or abnormal proteins would be best recognized by the host immune system. 
detectable in the epithelial cells of many normal tissues by immunohistochemical staining. The HER-2/ncu gene is present, in normal cells, as a single copy.9 Amplification of the gene, and/or overexpression of the associated protein, has been identified in many human cancers, such as breast, ovarian, prostate, non~sma11 cell lung cancer, and colon cancer.
The HER-2/neu oncogenic protein is also a tumor antigen. Patients with different tumor types that overexpress the HER-2/neu protein can have both antibody and T-cell immunity directed against HER-2/neu. Thus, a vaccine specific for the HER-2/neu protein may have wide applica tion in the treatment and/or pn.-'Vcntion of many different human malignancies. Existent immu nity to HER-2/neu in humans was initially described in patients with breast cancer. 10 Subse quently, several investigations have defined the incidence of HER-2/neu-specific antibodies in patients bearing a variety of carcinomas. HER-2/ neu antibodies at titers of >1:10 were detected in 12 of 107 (11%) breast cancer patients versus oof 200 (0%) in controls (p < 0.01).1 1 Detection of antibodies to HER-2/neu also correlated to overexpression of HER-2/neu protein in the patient's primary tumor. Nine of 44 (20%) pa tients with HER-2/neu-positive tumors had HER-2/neu-specific antibodies, whereas 3 of 63 (5%) of patients with HER-2/neu-negative tu mors had detectable antibodies (p == 0.03). The presence of HER-2/neu-specifie antibodies in breast cancer patients and the correlation with HER-2/neu-positive tumors implies that immu nity to HER-2/neu develops as a result of eJo..'P0 sure to HER-2/neu protein expressed by the patients' own cancer. Similarly, antibodies to HER-2/neu have been found in the sera of pa tients with colon cancer, and, again, the antibody presence correlates with overexpression of pro tein in the prj mal)' tumor (p < 0.01).12
Most recently, HER-21neu was demonstrated to be a shared tumor antigen in patients with prostate cancer. Antibody immunity to HER-21 neu was significantly higher in patients with pros tate cancer (15.5%, 31/200) compared with con trols (2%, 2/100, P == 0.0004), and titers greater than 1:100 were most prevalent in the subgroup of patients with androgen-independent disease (16%, 9/56). 13 Helper T-cell immunity to HER-2/neu has also been detected in patients with breast cancer. In an attempt to determine potential class II epitopes derived from the HER-2/neu protein, investigators took advantage of the pre-existent HER-2/ncu-specific immune response and screened patients with breast cancer for respon siveness to HER-2/neu-associated peptides.
14 One peptide, p777-78 9, elicited T -heIper responses in 10 of 18 patients studied. Our group recently evaluated HER-2/nen-specific T-cell immunity in 45 patients with stage III or IV HER-2/neu overexpressing breast or ovarian cancer. Patients had not received immunosuppressive chemo therapy for at least 30 days (median,S months; range, 1-75 months) prior to entry in the study, and all patients were documented to be immune co mpete nt by delayed -type hyp ersc nsitivi ty (DTH) testing using a skin test anergy battery. Five of 45 patients (11%) were found to have a significant HER-2/neu protein-specific T -cdl response, as defined by a stimulation index 22.0 (range, 2.o-7.9).1~
Studies detailing the cytotoxic T lympho cyte(s) (CTL) response to HER-2/neu have been hampered by the tack of available autologous tissues to assess lytic activity and the difficulty in propagating the type of tumors that overexpress HER-2/neu ex vivo. Many of the tumors in which HER-2/neu is overexpressed are hor monally driven and difficult to passage in vitro without substantial supplementation. Evalua tion ofHER-2/neu-specific CTL, therefore, is almost solely restricted to patients with ovarian and lung cancers, where malignant effusions act as a source of both tumor and T cells. Initial investigations identified HER-2/neu-specific CTL in the malignant ascites of human leuko cyte antigen (HLA) A2 patients who had HER 2/neu-overexpressing ovarian cancers. 16 CTL re active with autologous ovarian cancer appeared to recognize the peptide p971-980. Further studies with this peptide revealed it could be used to dicit peptide-specific CTL responses by in vitro stimulations with peripheral blood mononuclear cells (PBMC) obtained from ova rian cancer patients who were HLA-A2 and who had HER-2/neu-positive tumorsY Subse quently, HER-2/neu-specific eTL have been identified in patients with a variety of HER-21 neu-overexpressing cancers, including breast, ovarian, renal cell, and lung. 18,1~ Clinical laboratory studies defining the inci dence and magnitude of the immune responses to the HER-2/neu protein do more than simply identify HER-2/neu as a tumor antigen. Immu nity to a tumor antigen and a growing tumor can coexist in the same patient; therefore, the im mune responses generated by exposure to the tumor is not substantially effecting rumor growth. Most of the immune responses described above were of low magnitude.
Studies from our group have demonstrated that HER-2/neu-specific immunity can be boosted by active immunjzation. Peptide-based vaccines are an effective way to immunize against «self" -tumor antigens, such as HER-2/neu. 20 ,21 Peptide-based vaccines also offer the advantage of ease of synthesis and formulation, as well as the capability to apply highly quantitative meth ods to measure the tumor-specific immune re sponse generated after active immunization.
II. THE ROLE OF ANTIGEN EXPRESSION IN THE DESIGN AND APPLICATION OF PEPTIDE-BASED VACCINES
Studies in human and animal models of autoimmune disorders have documented that nor mal "self" -antigens can be the targets of immune attack and tissue destruction, giving credence to the concept of inducing antitumor immune re sponses. 22 In general, these autoimmune responses are to proteins highly expressed or overexpressed by the tissue. In human and murine autoimmune thyroiditis, for example, one of the main targets of an immune response is the highly expressed thyroglobulin. 23 Vaccination of mice against thyroglobulin results in destructive thyroiditis that is mediated by T cells.l 3 The overexpression of certain oncogenic pro teins in malignancy has suggested that they may be preferred target antigens for tumor immuno therapy. Our experimental model, HER-2/neu, for example, is markedly overexpressed in ap proximately 25% of breast and ovarian cancers and has been shown to be a poor prognostic factor for both discases. 24 ,25 Of note, patients with pre-existing antibody or T-cell immunity to HER-2/neu show no evidence of autoimmune toxicity, suggesting that antibodies and antigen specific T cells arise with overexpression of the oncogene and do not recognize cells with normal HER-2/neu expression. Similarly, rreatment of patients with a monoclonal antibody specific for HER-2/neu, Herccptin, has resulted in objective antitumor responses, but has not resulted to date in detectable adverse autoimmune reactions. 26
It has been suggested that vaccines for anti tumor therapies are likely to be most effective in states of minimal residual disease, when the vol ume of tumor burden is lowest. 27 . 28 However, active immunization might be used to prevent the establishment of antigen-overexpressing ma lignancies, with the plan to alter the biology of the disease. In the case of HER-2/neu, for ex ample, antigen overexpression has been clearly demonstrated in several early stage epithelial cell 25 cancers, including breast and ovarian cancers. 14 · The amount of HER-2/neu overexprcssion in primary prostate adenocarcinoma, however, has been the subject of debate. Most groups have suggested that overexpression of HER-2/neu is uncommon in primary prostate tumors com pared with primary breast cancers,29.W whereas overexpression is detected in a substantial num ber of metastatic disease specimens, and shed HER-2/neu protein can be detected in the sera of a majority of patients with metastatic dis ease. 3 1.32 This is consistent with the observation that HER-2/neu overexpression in prostate can cer cells can overcome the androgen-dependent growth inhibition and lead to androgen-indc pendef\t growth.'" Consequently, vaccine thera pies targeting HER-2/neu in prostate cancer, as an example, may be useful to prevent the estab lishment of a more malignant HER-2/neu ovcrexpressing phenotype. Thus, the differences in antigen expression during disease course may influence the design and application of human clinical studies.
III. ISSUES IN CLINICAL TRIAL DESIGN
The structure for clinical trial design of new therapeutic "anticancer" agents has been clearly defined by the Cancer Therapy Evaluation Pro gram (CTEP). CTEP is a program within the Division of Cancer Treatment and Diagnosis of the National Cancer Institute, which plans, as~e~~es, and coordinates aU aspects of clinical trials, including the application ofthe well-known structure of phase I-III trial designs. Phase I trials are, by definition, the format for initially testing a therapy or drug in humans'l4 and arc designated as the mechanism by which the maxi mally tolerated dose (MTD) of an agent is de fined. These trials are usually comprised of small patient groups to whom escalating doses of an agent are administered. The patient population is often varied and not necessarily representative of the group for whom the drug or treatment will eventually be best applied, but it is a group for whom there might not be other therapeutic options. It is not until phase 11 studies, after the safe dose has been defined, that the patient population becomes more refined and the experi mental endpoints include an evaluation of thera peutic efficacy.
The development of a cancer vaccine as a therapeutic strategy requires that we answer some unique biologic questions during the phase I study that do not focus on defining the classic maxi mally tolerated dose. Although safety is always an objective of phase I studies, and has significant relevance in our vaccine trials, defining the MTD is not a relevant endpoint because the goal of the intervention is developing immunity that may be linearly related to dose. Assessing the immuno genicity of the vaccine is as important an objec tive as safety. Several peptide vaccine studies in both infectious disease and tumor antigen sys tems have defined the immunologic dose range of peptide immunizations. Therefore, our initial phase I trials are not designed to compare doses of peptides, but to compare immunologic re sponses to the same dose of different peptides. Thus, we set as our objectives (1) to assess the toxicity associated with peptide-based vaccines targeting HER-2/neu, (2) to measure the cellular immune responses to 3 vaccine formulations (each comprised of 3 pep tides of the HER-2/neu pro tein), and (3) to compare the immune responses elicited by the 3 vaccine formulations. Trial de signs evaluating cancer vaccines demand a re thinking of some of the traditional biases that define patient selection, study objectives, and the approach to statistical analysis, which will give answers to endpoints that are biologic outcome measures and not measurements of toxicity.
J
A major consideration when selecting the patient population is to enroll a population that enables the investigator to answer the defined experimental questions. By definition, patients eligible for a phase I study must have confirmed malignant disease that is not satisfactorily treated by conventional forms of therapy or for which there is no standard treatment. There is a bias that cancer patients, either as a consequence of chemotherapy or the biology of their tumors, may not be able to mount a cellular immune response. A large number of studies over several decades have identified multiple problems with the immune system of a tumor-bearing host. Tumors may secrete soluble factors that dampen the immune response, major histocompatibility complex (MHC) molecules may be downregu lated, and T cells themselves may be nonfunc tional. 35 In addition, many patients with cancer have been treated with cytotoxic chemotherapy that, in itself, may result in delayed T-cell regen eration and T-cell subset imbalance.36 For ex ample) CD4' T cells are at 50% of normal levels for as long as 12 to 14 months after chemo therapy. Moreover, when stimulated by mito gens, there is an increased susceptibility for T cells from patients previously treated with chemo therapy to apoptose as compared with normal donorsY The assumption that an immune re sponse will be difficult to generate in the cancer patient has influenced the enrollment criteria of clinical vaccine studies and the interpretation of results.
We assumed that only cancer patients who were immune-competent could potentially be immunized with a tumor antigen-specific vac cine, yet only the most heavily pretreated subjects could be enrolled into a phase I study. Initiat ing a study in end-stage cancer patients might preclude us from answering the objective of the study: Can HER-2/neu peptide-based vaccines augment or elicit immunity in patients with HER 2/neu-overexpressing tumors? To avoid this prob lem, our enrollment criteria required that pa tients demonstrate immune competence by DTH testing to a battery of common recall antigens. In an analysis we perfonned on the first 53 patients evaluated for enrollment, 38 (72%) were not anergic. Among the 15 (28%) who were anergic, 7 were retested a median of 26 days (range, 12 150 days) after receiving a booster diphtheria tetanus (DT) vaccination. Five of the 7 had posi tive DTH responses when rechallenged w1th the DT antigens, and 6 had peripheral blood tetanus specific T-cell response with stimulation index ;::2.0. 38 Thus, DTH testing to a battery of common recall antigens may not adequately assess a cancer patient's ability to mount a cell mediated immune response follOw1ng vaccina tion. This observation was corroborated by an analysis of patient characteristics that could po tentially predict who could be immunized to the peptides in their vaccine formulation. A DTH response of >S mm to a common recall antigen, evaluated as an independent variable, did not predict for a subject having an immuni~d re sponse as defined by quantified antigen-specific T-cell proliferation.
Thc primary objective of a clinical study de fines the sample size of that study. To ensure that our measured results would have adequate statistical power we needed to have a larger sample size than traditionally seen in phase I trials. Vve established that in order to proceed with one of the vaccine formulations to a phase II trial, at least 50% of subjects should be ex pected to have an immunologic response. Thus, our initial phase I study was designed to enroll 60 patients with breast, ovarian, or non-small ceUlung cancer-or 20 patients per vaccine for mulation. While 20 patients per arm is a larger than-expected number for a toxicity study, if a response rate (defined as either the generation of or the augmentation of an immune response) is known for 20 patients, then the ability of a particular vacclne formulation to elicit these responses in a general population can be pre dicted. For example, if 20 patients were entered into a study and 14 responses (70%) were ob served, then the true response rate at a 90% confidence interval is 49 to 86% in a larger population. 39 Fewer than 20 subjects would not yield adequate information and 30 would not contribute more (Table 1) . Thus, the scientific endpoints of human clinical studies should be very clearly identified, and the clinical structure of the protocol modified to maximize obtaining a definitive answer to the proposed hypothesis.
IV. PATIENT CARE AND THE

ACQUISITION OF SAMPLES FOR LABORATORY ANALYSIS
The future success of a vaccine strategy may depend on adequate analysis of the immune re sponse generated during active immunization. The clinical issues related to immunologic monitori ng of these trials focus primarily on the acquisition of PBMC in suffi<.:ient quantities to perform real-time laboratory tests, as well as having a bank of specimens available for future study. The volume of blood necessary to accomplish this goal is significant and has numerous ramifiCa tions for patients agreeing to participate in these studies. Large quantities of lymphocytes are not readily available from cancer patients in the clinical setting.
One of the first questions in protocol devel opment, after the tests to be used for immuno logic monitoring have been detennined, is what quantity of PBMC is required to efficiendy per form immunologic monitoring? The answer to this question is largely determined by the kinds of immunologic assays to be performed. Two tests that are frequently used for immunologic moni toring in our lab are a modified CD4-limiting dilution analysis (mod-LDA) and ELISPOT. Both methods require significant numbers ofcells, 60 to 80 x 10 1 , cells, in order to perform the test with all appropriate controls. The yield ofPBMC from 60 mL of blood from a normal donor is usually 100 to 200 X 10 6 cells, whereas the yield from heavily treated cancer patients is one-half to one-third that of a normaJ donor: 50 to 150 X 10 6 cells per 60 mL of blood. Therefore, it would potentially require 2 to 3 times as much blood to perform the same test in a cancer patient as compared with a normal donor. If the yield of PBMC is small, it is possible that there may not be enough cells to perform all the necessary as says, and also to be able to freeze-back samples for future use. One way to determine if the yield from a given patient will be sufficient is to first obtain a lymphocyte count on the patient and estimate the yield from that value. This would necessitate 2 blood draws for each immunologic monitoring time point during the study and may not be practical in a patient population that does not usually have good peripheral venous access. An easier method that we have employed in our studies is to exclude patients w1th a white blood cell count less than 3.0 or a lymphocyte count less than 1.0. These criteria increase the likelihood that we will get enough PBMC to perform the immunologic monitoring assays that are a critical part of the study.
Very little has been published recently about the clinicaJ implications of large-volume blood drawing. Studies have been performed that de scribe hemoglobin regeneration after blood dona tion by normal donors. Fourteen heaJthy subjects donated 400 mL of blood, about 8% of their blood volume. The hemoglobin was noted to have nadired at 1 to 2 weeks, with a subsequent return to predonation levels in 3 to 4 weeks. Hemoglobin regeneration in cancer patients that have been heavily treated with chemotherapy is not well-defined. Based on studies in normal donors, it would be expected that a blood draw of 180 to 220 mL would decrease a patient's hema tocrit by 1 to 1.5%, depending on weight and baseline hematocrit. We evaluated baseline and follow-up hcmatocrits in 34 of 60 patients who received 6 vaccines as part of the study and who had blood drawn monthly for 7 months. The volume of blood taken from the patient at each draw ranged from 100 to 240 mL. The mean baseline hem atocrit was 37.1 and the mean follow up hematocrit was 37.4. The blood draws were generally well-tolerated, with only an occasional complaint of a slight increase in fatigue the day of, or day after, the blood draw.
Many cancer vaccine studies perform a leukapheresis before and after immunization, as a matter of course, for the collection of cells for monitoring. Patients enrolled in our HER-2/neu vaccine studies are mainly patients with breast cancer, the majority of whom have had lymph node dissection as part of the surgical resection of their tumors and, therefore, have only one arm available for blood drawing. Accessing veins in an arm on the side of a mastectomy predisposes a patient to the development oflymphedema (swell ing of the entire extremity). Lymphedema is a problem occurring in approximately 15 to 20% of breast cancer patients after lymph node dissec tion and/or radiation and can occur at variable time points after treatment. Lymphedema is disfiguring, can predispose patients to compli cations (such as infection and deep venous thrombosis), and can be insidious in its onset.
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In patients who have undergone lymph node dissection, the only means of performing the leukapheresis procedure is by placing a femoral or jugular venous catheter. This procedure is in vasive, costly, and not without risk; it should be considered very seriously before becoming a re quired procedure as part of a research study.
V. THE EVOLUTION OF LABORATORY ASSAYS TO CLINICAL ASSAYS FOR IMMUNE MONITORING
There are currently no standard validated methods for immunologic monitoring after im munization with a cancer vaccine. 41 The ideal clinical immunologic monitoring strategy is one that (1) uses a minimal amount of clinical mate rial, that is, analysis can be performed with a single tube of blood; (2) allows sensitive and specific analysis of cryopreserved cells; (3) re quires no ex vivo manipulation, such as in vitro simulation(s); (4) is highly quantitative and sen sitive to a broad range of responses; and (5) is amenable to multiple evaluations in a short pe riod of time, that is, it is easily automated. Sev eral novel methods of T-cell enumeration are becoming available and must be adapted for clinical use, for example, ELISPOT, intercellular cytokine staining by flow cytometry, and MHC class I tetramer analysisY The validation of these tests as clinical tools is critical to their evolution from laboratory to clinical tests.
Clinicians have an expectation that labora tory tests are backed by rigorous analyses that deflne bascline responses and validate the repro ducibility of results. This type of data is rarely published or discussed in the context of reporting results from cancer vaccine trials. Of note, the steps needed to determine validation data are well-defined. Qy.ality control monitoring and assay validation are composed of several analytical measures. These measures are routine, for the most part, for serologic studies, hut require effort in application to assessment of T -cell-based methods of immunologic monitoring.
First is an assessment of accuracy. Accuracy refers to the correctness and exactness of the test result, it is defined as the closeness of a test result to the true value, and it can only be calculated by comparison to a standard. Deflnitions of stan dards are difEcult for T-cell assays. T-cell clones specifiC for infectious disease or tumor antigens would be useful controls to determine the accu rate performance of T-cell assays for immuno logic monitoring.
A second important measure is precision, or the reproducibility of the test. Precision is de fined as the closeness of the test results to one another when using the same specimen. Preci sion is expressed as a standard deviation (SD) and coefficient of variation (CV) of multiple sample runs. The same sample can be run multiple times on the same day-inaaassay precision-or the same sample can be run multiple times over several days-interassay precision. Identification of known positive specimens and multiple repli cate runs will establish assay precision.
Sensitivlty is the limit ofdetection of a method or the capacity of the method to detect small amounts of a substancc with some assurance. Sensitivity is assessed by spiking a negative sample with known guantities of well-characteri~d T cells Of using interferon (lFN)-y-coated beads in place of cells in the case of ELISPOT.
Specificity is the ability of a method to mea sure only the substance being tested. Interference assays, which dilute a defined T-cell population with one of a different specificity than the one being tested, for example, diluting a specific number of flu T-cell clones with c.rvrv clones and analyzing for flu-specific responses, allows an estimation of the specificity of the analysis. Finally, the last step is the correlation of the validated test with a clinical measure.
The reliability of a method describes the ability of the test to maintain accuracy, precision, sensitivity, and specificity despite changes in ex ternal factors, such as technicians, instruments, or reagents. An assessment of reliability is made using a we1\-characterized reference population. The reference population is the group of indi viduals assessed to determine the parameters of a "normal" value. If the well-defined values of this group fluctuate significantly with changes in the test, the assay is probably not reliable enough for repetitive use or application to the measurement oflarge numbers of samples. The challenge is to develop reproducible assays for the quantitation of immunity when there is no "gold standard" with which to compare them.
VI. A PHASE I STUDY OF HER-21NEU PEPTIDE-BASED VACCINES
Vie initiated phase 1 clinical trials to assess both toxicity and immunogenicity of 3 unique HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing tumors. The helper peptides used in this study were identified using the MHC class II-motif search program, Tsites. 41 In preclinical studies, it was observed that low but signifiCant, levels of natural im munity to the peptides existed in patients with HER-2/neu-overexprcssing cancers. We enrolled a total of 63 patients with late stage breast (n == 53), ovarian (n == 8), or non-smalJ ceHlung (n == 2) cancer. All of the patients had definitive con ventional therapy and had no evidence of disease. Each vaccine was composed of 3 peptides, 14 to 18 amino acids in length.21 Two vaccine prepa rations contained helper epitopcs that targeted either the extracellular domain (ECD) of HER 2/neu (p42-56, p98-114, p328-34S) or the intra cellular domain (leD) of HER-2/neu (p776 790, p927-941, P1166-1180).43 The other vaccine preparation (HLA-A2 vaccine) consisted of 3 putative T -helper epitopcs (p369-384, p688-703, p971-984), each of which contained a complete HLA-A2 binding motif (p369-377, pfi89-697, p971-979) within its sequences.
44 G M -CSF was used as an adjuvant,45 and the immunizations were administered intradennally monthly for 6 months. The patients had a median age of 49 years and the median time from chemotherapy was 6 months.
All of the vaccines were well tolerated; only minimal toxicities were observed and were limited to skin and myalgia, with the majority being grade 1. In our interim analysis of patients who completed 6 vaccines, it was observed that the majority of the patients (>50%) developed T-cell immunity to their immunizing peptidcs as as sessed by T-cell proliferation assays, SJ. :::: 2.0. Recently, it has been reported that T -cells in duced by peptides are unable to recognize the antigen processed and presented naturally.46 For our phase I trial, protein-specific T -cen responses were assessed in vitro using recombinant HER 2/neu proteins, ECD and lCD. Following im munization, we observed that, similar to the pro Jiferative response rate to the vaccine peptides, greater than 50% of patients who received the full course of 6 vaccinations were able to respond directly to recombinant proteins. This suggests that at least one of the peptides contained within their vaccines was presented naturally.
Patients also developed DTH responses to the HER-2/neu peptides. The assessment ofboth T -cell proliferation and DTH together has shed light on the value of the DTH measurements during immunization against tumor antigens. An analysis of the first 32 consecutive patients who completed 6 vaccines demonstrated that the DTH response is a predictor of peripheral blood T-cell immunity following vaccination. A highly sig nificant statistical association was observed be tween positive T-cell proliferation responses (5.1. :::: 2) and development of DTH (:::: 10 mm 2 )Y The observation that CD8 T cells can di rectly lyse tumor cells has led to the identification of several MHC class I epitopes from tumor antigens, including HER-2/neu. 1 l<.14.48,49 Direct clinical application of MHC class I epitopes in vaccine or treatment trials, however, has been largely unsuccessful due to the generation of only low-level or undetectable immune responses. The necessity of concurrent generation of both CD4 and CD8 T-cell responses has been clearly demonstrated for effective viral immunity and lasting protection.50 Recent evidence suggests that CD4 activation may be important for tumor specific immunity as well. 51 • 52 Thus, efforts are under way to develop vaccines that induce both T-cell subsets.
The HER-2/neu HLA-A2 vaccine described above was designed to meet this objective. Nine teen HLA-A2 pacieots were enrolled in this ann of the clinical trial. Peripheral blood from these pa tients was examined for T-cell precwsors specific for the encompassed HLA-A2 motifS. Following vaccination, greater than 60% of subjects devel oped peptide-specific precursors for one or more of the encompassed motifs as assessed by IFN-y based ELISPOT. Peptide-specific CD8 T-cell pre cursors ranged from <1:100,000 to 1:2100 follow ing vaccination. Vaccination resulted in the development of HER-2/neu immunity in many patients that was similar to the endogenous viraJ (influenza and CMV) immunity observed. The peptide-specific T cells were also able to lyse HER 2/neu-overexpressing cell lines, demonstrating natural presentation ofone or more of the peptides. In one representative ovarian cancer patient, 21 p369-377 9-mer-specific clones were isolated fol lowing vaccination.53 The majority (19/21) of the clones expressed CD3. Vlhile 11 ofthe clones were CD8+, 9 were CD4+ despite being cloned with the HLA-A2 9-mer. Also, 19 of the clones expressed the <X~ T-cell receptor (TCR), and, interestingly, 2 expressed the yo TCR,54 Both aJ3-and yo-TCR clones were able to lyse HER-2-overexpressi ng ovarian cancer cells. Many of the clones examined were type I, as indicated by secretion of both IFN-y and TNF-<X.
VII. CONCLUSION
The design of a clinical trial of a cancer vaccine is as important as the design of the laboratory experiments executed to develop the therapeutic strategy. The choice of the patient population to be immunized and the laboratory methods used to assess immunization must bc defined in terms of the therapeutic goal of the
